Nasdaq:
PGEN Russell 2000 Component | |
Industry | Biotechnology |
Founded | May 21, 1998 |
Headquarters | |
Revenue | $91 million (2019) [1] |
Number of employees | 600 |
Website |
precigen |
Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. [2] [3] With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. [4]
In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million. [5] In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia. [6] [7] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing. [8] [9] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk. [7]